Weekly NADAC Price Changes
A weekly executive brief covering the pricing movements that matter most to market strategy and reimbursement planning.
Pricing pressure broadened across endocrine and respiratory products as a small set of high-volume therapies drove the week’s largest shifts.
The latest release shows a concentrated pattern of movement rather than a broad market-wide reset. Most of the week’s largest increases were concentrated in a narrow group of high-exposure products, while relief remained more fragmented across lower-cost oral therapies.
Key takeaways
- Endocrine products posted the largest weighted movement this week.
- The biggest increases were concentrated in high-exposure therapies rather than across the entire market.
- Downward movement remained fragmented, suggesting pricing relief is still uneven.
What to watch
Endocrine pressure
Whether the largest increases continue to be driven by a small number of high-exposure NDCs.
Respiratory volatility
Whether volatility broadens beyond the current concentration of price swings.
Manufacturer shifts
Whether supply-side pricing moves begin to spread across more products in the next release.
Largest cost pressure
Largest absolute weekly price increase in the current release
Largest relief
Largest absolute weekly price decline in the current release
Top 10 NDCs by weekly price movement
Up to 10 changed products are shown. Each edition preserves its published price comparison.
| Drug | Manufacturer | NDC | Prev. price | Current price | Change |
|---|---|---|---|---|---|
| AMLODIPINE BESYLATE 10 MG TAB | ACI Healthcare USA, Inc. | 71093014803 | $0.4210 | $0.5814 | +38.1% |
| DONEPEZIL HCL 10 MG TABLET | ACI Healthcare USA, Inc. | 71093012801 | $0.0624 | $0.0838 | +34.2% |
| GABAPENTIN 300 MG CAPSULE | ACI Healthcare USA, Inc. | 71093012104 | $0.0248 | $0.0199 | -19.8% |
| METFORMIN HCL 1,000 MG TABLET | ACI Healthcare USA, Inc. | 71093013404 | $0.1146 | $0.0935 | -18.4% |
| 12-HR DECONGEST 120 MG CAPLET | Topco Associates LLC | 36800005460 | $0.7100 | $0.7284 | +2.6% |
| 12HR NASAL DECONGEST ER 120 MG | Cardinal Health | 70000047501 | $0.0782 | $0.0896 | +14.6% |
| 24HR ALLERGY(LEVOCETIRZN) 5 MG | Cardinal Health | 70000036202 | $0.0627 | $0.0541 | -13.7% |
| 4 WAY 1% NASAL SPRAY | Haleon US Holdings LLC | 00067208601 | $0.0958 | $0.0812 | -15.3% |
| 24H NASAL ALLERGY 55 MCG SPRAY | AmerisourceBergen | 46122038576 | $0.2675 | $0.3094 | +15.7% |
| INFANT'S GAS RLF 20 MG/0.3 ML | AARNA USA Inc. | 82568001703 | $0.1942 | $0.1684 | -13.3% |
Drug market summaries
Manufacturer movement
Notes and methodology
How the weekly brief calculations were ranked, aggregated, and preserved for archive consistency.
Top mover ranking
The Top 10 table ranks NDCs by absolute weekly impact: the change in unit price multiplied by dispensing exposure when available.
Segment summaries
Drug markets, manufacturers, and therapeutic classes aggregate the same NDC-level deltas. Average move is the mean percent change, while impact is the summed dollar-weighted effect using absolute price impact because dispensing-volume weighting was unavailable.
Headline cards and archive stability
Most pressured class selects the largest positive class impact, and largest manufacturer swing selects the manufacturer with the largest aggregate absolute impact. Every weekly brief stores a frozen snapshot so archived pages do not drift when live NADAC data changes.
Recent editions
Each edition is permanently archived under its release date.
Week of August 12, 2026
Respiratory and cardiovascular names led a narrower repricing week as supplier-level changes remained concentrated rather than market-wide.
The prior release showed a more selective set of price resets, with supplier-specific moves driving most of the measured impact. Relief showed up in several established cardiovascular therapies, but broad deflation still did not develop across the full market.
Week of August 5, 2026
Pricing pressure remained focused in a smaller set of anti-infective and endocrine products while broad supplier dispersion stayed relatively stable.
This release leaned more heavily on product-specific resets than on broad-based category repricing. Anti-infective moves stood out in percentage terms, but endocrine names still accounted for the largest weighted pressure across higher-volume products.
Explore the broader trend ecosystem
Trends overview
Broader market movement and volatility across the full NADAC dataset.
Manufacturers
Compare suppliers and pricing dispersion across product portfolios.
Drug markets
Review generic alternatives by therapeutic market and current pricing.
Therapeutic classes
See category-level swings by prescribing class and market segment.
Understanding NADAC pricing
A primer on how NADAC works and why weekly movement matters.
Methodology
How the data is normalized and aggregated for public reporting.